GIPR and Obesity: Co-localization analysis suggested that LPL (as a TG-lowering drug target), CETP (as an HDL-raising drug target), ABCC8 (as a glucose-lowering drug target) and GIPR (as an anti-obesity drug target) were unlikely to share a causal variant with LS (Supplementary Table 11).